×
0 0 -0.000882612533097951 0.00617828773168581 0.000882612533097951 -0.0114739629302735 -0.000882612533097951 -0.00970873786407762
Stock impact report

Dermira up 3% premarket on start of late-stage development of lebrikizumab [Seeking Alpha]

Dermira, Inc (DERM)  More Company Research Source: Seeking Alpha
Last dermira, inc earnings: 8/7 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.dermira.com
PDF Dermira up 3% premarket on start of late-stage development of lebrikizumab Dosing is underway DERM The late-stage program will include another identical Phase 3. Total enrollment in the two studies will be ~800 subjects across ~200 sites in the U.S., Europe and Asia. Topline data from the 16-week induction period should be available in H1 2021. Almirall S.A. ( OTC:LBTSF DERM is up 3% [Read more]
Impact snapshot Event time: DERM
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
DERM alerts

from News Quantified
Opt-in for
DERM alerts

from News Quantified